GRDN vs LTC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GRDN and LTC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GRDN and LTC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Guardian Pharmacy Services runs closed-door pharmacies, not storefronts. Its pharmacies do not serve walk-in customers: they serve facilities, handling routine cycle fills, compliance packaging sorted by resident and dose time, urgent and after-hours deliveries, integration with facility electronic medication administration records, and the reimbursement work of billing Medicare Part D, Medicaid and commercial payors. The deliberate difference versus the incumbents is the customer type. More than two thirds of revenue comes from assisted living facilities and behavioral health facilities rather than the skilled nursing homes where Omnicare and PharMerica hold most of the share. Guardian also operates unusually for a roll-up: acquired and greenfield pharmacies are run by a local president who typically keeps a minority equity stake in that pharmacy, while corporate supplies purchasing scale, technology, billing and back office. As of March 31, 2026 that network was ~61 licensed pharmacies, ~54 of them full service, across 38 states. The company was founded in 2003 and listed on the NYSE in September 2024.

Full GRDN guide

LTC Properties is a real estate investment trust that owns and finances seniors housing and skilled nursing facilities, holding roughly 180 investments across about 27 states with a couple dozen operating partners. Historically it collected rent through triple-net leases (where operators pay taxes, insurance, and maintenance) and earned interest on mortgage loans, giving it a landlord-style, predictable income stream. It has long been known to income investors as a monthly dividend payer.

Full LTC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GRDN drivers: Resident growth is running well ahead of reported revenue; A repeatable acquisition and greenfield flywheel.
• LTC drivers: SHOP / RIDEA transition to operated senior housing; Aging-population demand tailwind.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Reimbursement is the structural risk and it is not hypothetical: the IRA Part D redesign already cut prices roughly 60% on the affected portion of Guardian's branded book, and further legislative or CMS changes, plus ongoing PBM rate pressure, could compress economics again with little notice. For LTC, the SHOP model removes the buffer of triple-net leases and exposes LTC directly to operating costs, labor, and occupancy swings, so a downturn at a few communities can hit earnings faster than under a lease structure.

Pick GRDN if you believe its drivers more; LTC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GRDN and LTC guides.

GRDN. The reported growth rate understates the business right now: residents and scripts both grew high single digits while revenue grew ~2%, because IRA pricing removed drug dollars that carried almost no margin. That is why gross margin widened from ~20.2% in fiscal 2025 to ~21.6% on a trailing basis, and why adjusted EBITDA guidance has been raised three times in 2026. At ~$39.48 on October 16, 2026 the stock sits about 18% below its 52-week high but still trades near 38 times trailing earnings, a multiple closer to a compounding services roll-up than to a drug distributor; third-quarter results, expected around November 9, 2026, carry a consensus of about $0.31 of EPS on roughly $366 million of revenue.

LTC. At about $43.61 LTC trades near 1.85 times book value and close to the top of its 52-week range, after a rerating driven by the SHOP buildout. The seven analysts covering it have a mean target of about $46, and RBC raised its target to $52 from $45 in October 2026. For a REIT, FFO and FAD per share and dividend coverage are more meaningful than plain EPS, which is distorted by property gains and acquisition accounting.

Headline figures (approximate, October 2026): GRDN shows revenue (ttm) ~$1.46 billion; latest quarter up ~2.2% year over year, q2 2026 revenue ~$351.8 million, up ~2% (beat the ~$340 million consensus), q2 2026 adjusted ebitda ~$29.7 million, up ~19% from ~$25.0 million, net income / eps (ttm) ~$65.9 million, ~$1.03 diluted EPS (Q2 EPS ~$0.29 vs ~$0.26 consensus); LTC shows revenue (ttm) ~$340M (Q2 2026 ~$99M, up ~65% YoY), net income (ttm) ~$135M (includes a large Q4 2025 gain), q2 2026 per-share result ~$0.47 vs ~$0.44 estimate, dividend (annualized) ~$2.28/share, paid monthly.

GRDN and LTC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GRDN and LTC exposure against your real portfolio. It is not an investment adviser.